

**Coronavirus disease 2019 (COVID-19)-associated hospitalization and mortality in patients  
with psoriasis - A population-based study**

Khalaf Kridin MD, PhD<sup>1,2</sup>; Yochai Schonmann MD, MSc<sup>3</sup>; Dana Tzur Bitan PhD<sup>4</sup>;

Giovanni Damiani M.D.<sup>5</sup>; Alon Peretz MD, MOccH<sup>3</sup>, MHA ;Orly Weinstein MD, MPH<sup>3,6\*</sup>;

Arnon D. Cohen MD, PhD<sup>3,6\*</sup>

**American Journal of Clinical Dermatology, 2021**

**Supplementary Table 1:** Comorbidities of the study population of patients with psoriasis and COVID-19.

<b>Characteristic</b>	<b>Patients with psoriasis and COVID-19 (N=3,151)</b>
<b>Comorbidities, n (%)</b>	
Ischemic heart disease	271 (8.6%)
Congestive heart failure	80 (2.5%)
Cerebrovascular disease	126 (4.0%)
Dyslipidemia	1,214 (38.5%)
Hypertension	705 (22.4%)
Diabetes mellitus	552 (17.5%)
Obesity	1,037 (32.9%)
COPD	109 (3.5%)
Asthma	288 (9.1%)
Smoking	955 (30.3%)
Cirrhosis	8 (0.3%)
Chronic renal failure	116 (3.7%)
Malignancy	228 (7.2%)
Depression	223 (7.1%)
A history of Tuberculosis	9 (0.3%)

**Abbreviations:** n, number; COPD, chronic obstructive pulmonary disease;